Xifaxan (rifaximin) - Alfa Wassermann, Bausch Health
Gut microbiota and innate immune barrier dysfunction in hepatic portal venous gas: a hypothesis-generating review. (PubMed, Front Immunol) - Oct 21, 2026 - "Portal vein thrombosis, portal hypertension, pneumatosis intestinalis, pyogenic liver abscess, and HPVG may share the portal vein as a conduit but are not interchangeable. No microbiota-directed intervention has been tested against an HPVG endpoint and none should delay source control; probiotics, rifaximin, fecal microbiota transplantation, diet, and phage remain research questions." 
Journal • Review • Cardiovascular • Fibrosis • Hematological Disorders • Hepatology • Hypertension • Immunology • Inflammation • Liver Failure • Mucositis • Portal Hypertension • Reperfusion Injury • Thrombosis • Transplantation • TLR4
http://www.ncbi.nlm.nih.gov/pubmed/42898941
 
Che Wang; Lei Shi; Lianxiang Cui; Lin Zhu; Ping Zhou; Xiaoshuai Bai; Yanfei Shi; Yibo Sun
 
Oct 21, 2026
 
Prev Next